Literature DB >> 32157711

Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.

Shunji Nagai1, Toshihiro Kitajima1, Sirisha Yeddula1, Reena Salgia2, Randolph Schilke3, Marwan S Abouljoud1, Dilip Moonka2.   

Abstract

BACKGROUND AND AIMS: Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) policy mandates a 6-month waiting period before exception scores are granted to liver transplant candidates with hepatocellular carcinoma (HCC). This study aims to evaluate waitlist and posttransplant outcomes in patients with HCC, before and after implementation of the 6-month waiting rule. APPROACH AND
RESULTS: We examined two groups from the UNOS registry: Group 1 (pre-6-month rule) consisted of patients registered as transplant candidates with HCC from January 1, 2013, to October 7, 2015 (n = 4,814); group 2 (post-6-month rule) consisted of patients registered from October 8, 2015, to June 30, 2018 (n = 3,287). As expected, the transplant probability was higher in the first 6 months after listing in group 1 than group 2 at 42.0% versus 6.3% (P < 0.001). However, the 6-month waitlist mortality/dropout rate was lower in group 2 at 1.2% than group 1 at 4.1% (P < 0.001). To assess regional parity of transplant, UNOS regions were categorized into three groups based on Model for End-Stage Liver Disease score at transplant: lower-score (regions 3, 10, and 11), middle-score (1, 2, 6, 8, and 9), and higher-score region groups (4, 5, and 7). Outcomes were compared from the time exception points were given, which we defined as conditional waitlist outcomes. Conditional waitlist mortality/dropout decreased, and transplant probability increased in all region groups, but the benefits of the policy were more pronounced in the higher and middle-score groups, compared with the lower-score group. The decline in waitlist mortality/dropout was only significant in the high Model for End-Stage Liver Disease group (P < 0.001). No effect was observed on posttransplant mortality or percent of patients within Milan criteria on explant.
CONCLUSIONS: The HCC policy change was associated with decreased waitlist mortality/dropout and increased transplant probability. The policy helped to decrease but did not eliminate regional disparities in transplant opportunity without an effect on posttransplant outcomes.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2020        PMID: 32157711     DOI: 10.1002/hep.31223

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.

Authors:  Sarah Bernards; Ryutaro Hirose; Francis Y Yao; Chengshi Jin; Jennifer L Dodge; Chiung-Yu Huang; Neil Mehta
Journal:  Liver Transpl       Date:  2021-12-08       Impact factor: 5.799

Review 2.  Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach.

Authors:  Adam Swersky; Laura Kulik; Aparna Kalyan; Karen Grace; Juan Carlos Caicedo; Robert J Lewandowski; Riad Salem
Journal:  Semin Intervent Radiol       Date:  2021-10-07       Impact factor: 1.780

3.  T2 Hepatocellular Carcinoma Exception Policies That Prolong Waiting Time Improve the Use of Evidence-based Treatment Practices.

Authors:  Claire Durkin; David E Kaplan; Therese Bittermann
Journal:  Transplant Direct       Date:  2020-08-21

4.  Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma.

Authors:  Anjiya Shaikh; Karthik Goli; Nicole E Rich; Jihane N Benhammou; Saira Khaderi; Ruben Hernaez; Vatche G Agopian; John M Vierling; Donghee Kim; Aijaz Ahmed; John A Goss; Abbas Rana; Fasiha Kanwal; George Cholankeril
Journal:  Transplant Direct       Date:  2022-04-12

5.  Race/Ethnicity Is Not Independently Associated with Risk of Adverse Waitlist Removal among Patients with HCC Exception Points.

Authors:  Daniela Goyes; John Paul Nsubuga; Esli Medina-Morales; Romelia Barba; Vilas Patwardhan; Behnam Saberi; Zachary Fricker; Alan Bonder
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

Review 6.  Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation.

Authors:  Kohei Ogawa; Yasutsugu Takada
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

Review 7.  Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors.

Authors:  Qimeng Gao; Imran J Anwar; Nader Abraham; Andrew S Barbas
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

8.  Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma.

Authors:  Mohamed Saleh Ismail; Islam Mohamed; Efstathia Polychronopoulou; John A Goss; Yong-Fang Kuo; Fasiha Kanwal; Prasun K Jalal
Journal:  J Hepatocell Carcinoma       Date:  2021-06-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.